Roxadustat may be beneficial to COVID-19 patients as it can reduce the level of angiotensin-converting enzyme-2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), which is associated with the entrance and replication of SARS-CoV-2 in lung epithelial cells [65]. This evidence concerns the gene TMPRSS2 and COVID-19.